Biotech News

MIMEDX Announces Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification Matter

MiMedx (MDXG)MiMedxFDA / regulatory

Court Vacates FDA Determinations That AXIOFILL Is Not Minimally Manipulated and Should Be Classified as a Biological Product Order Further Holds That Minimal-Manipulation Analysis Must Consider Tissue Characteristics Relevant to Reconstruction, Repair or Replacement in the Recipient MARIETTA, Ga.,

Related news

MiMedx

Placental Tissue Products MIMEDX develops and commercializes placental-tissue products for wound care, burns and surgery. Its processing and product portfolio are designed to provide extracellular-matrix and biologic materials that support healing and tissue repair. Wound-Care Portfolio The company has more than a decade of experience...

Recent company news

Stock data

Close
3.11 USD
Market cap
531.74M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States